新发转移性头颈癌的转移模式、结局与预后因素:按肿瘤HPV状态分析
该研究回顾2001至2024年诊断的cM1 HNSCC患者,描述转移特征与治疗模式。在10273例新诊断HNSCC中222例(2.2%)为cM1;中位OS为7个月,LR-RT、HPV相关疾病、ECOG 0-1、一线免疫治疗及仅肺转移与更长OS相关。
要点
- cM1 HNSCC仅占新诊断HNSCC的2.2%,中位OS为7个月,预后差。
- LR-RT(HR 0.49)、HPV相关疾病(HR 0.62)、一线免疫治疗(HR 0.52)与更长OS相关。
- 接受LR-RT者中,放疗剂量≥50 Gy与改善OS相关(HR 0.53)。
核心结论
- cM1 HNSCC预后差,存在显著未满足需求;一线免疫治疗和LR-RT(尤其≥50 Gy)与改善OS相关,值得前瞻性评估。
研究设计与样本
- 回顾性分析2001至2024年诊断的cM1 HNSCC患者,收集转移特征和治疗模式,采用Kaplan-Meier法估计OS,多变量Cox回归分析识别预后因素。
主要发现
- 在10273例新诊断HNSCC中,222例(2.2%)为cM1疾病;HPV相关组48/2593例(1.9%),HPV无关组174/7680例(2.3%)。
- HPV相关与HPV无关cM1患者的寡转移(1-5个病灶)比例分别为31%和43%(p=0.21),仅肺转移比例分别为83%和77%(p=0.46),但HPV相关组纵隔受累更常见(40% vs 23%,p=0.034)。
- 191例(86%)接受LR-RT:127例(57%)为唯一治疗,55例(25%)在一线系统治疗前,9例(4%)在一线系统治疗后。
- 中位随访25个月,中位OS为7个月(6.0-8.8)。
- 多变量分析显示,LR-RT(HR 0.49 [0.32-0.75])、HPV相关疾病(HR 0.62 [0.43-0.88])、ECOG 0-1(HR 0.63 [0.47-0.86])、一线免疫治疗(HR 0.52 [0.33-0.82])及仅肺转移(HR 0.67 [0.48-0.95])与更长OS相关。
临床怎么用
- 对于cM1 HNSCC患者,可考虑一线免疫治疗和LR-RT(尤其剂量≥50 Gy),但需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe metastatic characteristics and outcomes in patients with de novo metastatic (cM1) head and neck squamous cell carcinoma (HNSCC). METHODS: cM1 HNSCC patients diagnosed between 2001 and 2024 were reviewed. Metastatic characteristics and management patterns were collected, including the timing of locoregional radiotherapy (LR-RT) relative to first-line systemic therapy. Overall survival (OS) was estimated using the Kaplan-Meier method, and multivariable Cox regression analyses (MVA) identified prognostic factors. RESULTS: Among 10,273 newly diagnosed HNSCC cases, 222 (2.2%) had cM1 disease (HPV-associated: 48/2593 [1.9%]; HPV-independent: 174/7680 [2.3%]). cM1 characteristics were similar between HPV-associated and HPV-independent disease, including oligometastatic presentation (1-5 lesions; 31% vs 43%, p = 0.21) and frequency of lung-only metastases (83% vs 77%, p = 0.46), although mediastinal involvement was more common in HPV-associated disease (40% vs 23%, p = 0.034). LR-RT was delivered to 191 (86%) patients: 127 (57%) as sole treatment, 55 (25%) before, and 9 (4%) after first-line systemic therapy. After median follow-up of 25 months, median OS was 7 months (6.0-8.8). On MVA, LR-RT (HR 0.49 [0.32-0.75]), HPV-associated disease (HR 0.62 [0.43-0.88]), ECOG 0-1 (HR 0.63 [0.47-0.86]), first-line immunotherapy (HR 0.52 [0.33-0.82]), and lung-only metastases (HR 0.67 [0.48-0.95]) were associated with longer OS. Among patients receiving LR-RT, a radiation dose ≥ 50 Gy was associated with improved OS (HR 0.53 [0.34-0.83]). CONCLUSIONS: cM1 HNSCC has a poor prognosis, highlighting a substantial unmet need. First-line immunotherapy and LR-RT, particularly with ≥ 50 Gy, were associated with improved OS and warrant prospective evaluation.
引用
- Rühle A, Sanz-Garcia E, Su J, et al. Metastatic patterns, outcomes, and prognostic factors in de novo metastatic head and neck cancer by tumor HPV status. Radiother Oncol. 2026. PMID: 42697275. doi:10.1016/j.radonc.2026.111769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。